Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at UCSF

Sites in San Francisco, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1398
Shown on this page
12
Current sort
Recently updated
Campus scope
UCSF, San Francisco, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within UCSF, San Francisco, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 865–876 of 1,398 matching trials with a site at UCSF, San Francisco, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Not yet recruiting Phase 3 Interventional

PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study

NCT07670650
Site status not listed — check the official record
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
SAB-142, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
5 Years to 40 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 30, 2026, 6:19 PM EDT
Recruiting Phase 2 Interventional

Combination Therapy for the Treatment of Diffuse Midline Gliomas

NCT05009992
Status at this site: Recruiting
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent WHO Grade III Glioma, WHO Grade III Glioma
Interventions
ONC201, Radiation Therapy, Paxalisib, DNX-2401
Drug · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years to 39 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 30, 2026, 6:19 PM EDT
Recruiting Phase 2 Interventional

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

NCT05650229
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Primary Mitochondrial Disease
Interventions
KL1333, Placebo
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Orange, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 30, 2026, 6:19 PM EDT
Recruiting Phase 2 Interventional

A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure

NCT07615010
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Pneumonia
Interventions
agenT-797, Placebo, Standard of Care (SOC)
Drug
Lead sponsor
MiNK Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
San Francisco, California • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 30, 2026, 6:19 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

AlloSure Lung Assessment and Metagenomics Outcomes Study

NCT05050955
Site status not listed — check the official record
View directory record Official record
Conditions
Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection
Interventions
Not listed
Lead sponsor
CareDx
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 30, 2026, 6:19 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Troriluzole in Adult Participants With Spinocerebellar Ataxia

NCT03701399
Site status not listed — check the official record
View directory record Official record
Conditions
Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10
Interventions
troriluzole, Placebo
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 30, 2026, 6:19 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma

NCT06118086
Status at this site: Recruiting
View directory record Official record
Conditions
Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma
Interventions
REM-422
Drug
Lead sponsor
Remix Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
San Francisco, California • Tampa, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 30, 2026, 6:19 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

NCT07221162
Site status not listed — check the official record
View directory record Official record
Conditions
COVID-19
Interventions
Aluminum Hydroxide Suspension, Boost-2867, CpG 7909, Sodium Chloride, 0.9%
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
8
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 30, 2026, 6:19 PM EDT
Recruiting No phase listed Observational

A Study to Assess Growth in Children With Idiopathic Short Stature

NCT06309979
Status at this site: Recruiting
View directory record Official record
Conditions
Idiopathic Short Stature
Interventions
Not listed
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
2 Years to 16 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2040
U.S. locations
38
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 30, 2026, 6:19 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

NCT02425904
Site status not listed — check the official record
View directory record Official record
Conditions
Langerhans Cell Histiocytosis
Interventions
Clofarabine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 30, 2026, 6:19 PM EDT
Active, not recruiting Phase 2 Interventional

Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib

NCT05323955
Site status not listed — check the official record
View directory record Official record
Conditions
Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
Interventions
Trastuzumab, Trastuzumab Emtansine (T-DM1), Pertuzumab, Tucatinib
Drug
Lead sponsor
Carey Anders, M.D.
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 30, 2026, 6:19 PM EDT
Active, not recruiting Not applicable Interventional

Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)

NCT03838445
Site status not listed — check the official record
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
V-Wave Interatrial Shunt
Device
Lead sponsor
V-Wave Ltd
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 30, 2026, 6:19 PM EDT

About this UCSF institution page

What this page lists
ClinicalTrials.gov records that list UCSF in San Francisco, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by University of California, San Francisco at any site, browse by condition, or browse by U.S. city.